{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:07:07Z","timestamp":1780628827687,"version":"3.54.1"},"reference-count":60,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin disease with a significant clinical, economic, and human burden. The JAK1 Atopic Dermatitis Efficacy and Safety (JADE) program's Phase 3 trials demonstrated that as a treatment for moderate\u2010to\u2010severe AD in adults with previous exposure to immunotherapy, abrocitinib showed superior efficacy and safety compared with standard of care (SoC), consisting of topical corticosteroids. This study assessed the cost\u2010effectiveness of abrocitinib with SoC versus SoC alone for this patient population in Japan from a societal perspective. A hybrid decision tree and Markov model were used to capture the initial treatment and long\u2010term maintenance phases. Clinical inputs at 16\u2009weeks were obtained through a Bayesian network meta\u2010analysis of four pivotal trials from the JADE program. Clinical inputs at 52\u2009weeks were derived from the JADE EXTEND trial. Response\u2010specific utility inputs were obtained from published literature. Resource use, costs, and productivity inputs were gathered from Japanese claims analysis, literature, public documents, and expert opinion. Costs and quality\u2010adjusted life years (QALYs) were discounted at 2.0% per year and incremental cost\u2010effectiveness ratios (ICERs) were calculated. Sensitivity and scenario analyses were performed to validate the base case results and explore a payer perspective. Over a lifetime horizon and with the base\u2010case societal perspective, abrocitinib produced a mean gain of 0.75 QALYs, incremental costs of JPY (\u00a5) 2\u2009270\u2009386 (USD [$] 17\u2009265.6), and a resulting ICER of \u00a53\u2009034\u2009514 ($23\u2009076.5) per QALY compared with SoC. From a payer perspective, the incremental costs increased to \u00a54\u2009476\u2009777 ($34\u2009044.4), with an ICER of \u00a55\u2009983\u2009495 ($45\u2009502.6) per QALY. The results were most sensitive to treatment\u2010specific, response\u2010based utility weights, drug costs, and productivity\u2010related inputs. From a Japanese societal perspective, abrocitinib demonstrated superior QALYs and with a willingness\u2010to\u2010pay threshold of \u00a55\u2009000\u2009000 ($38\u2009023.4) per QALY, can be considered cost\u2010effective compared with SoC as a treatment for moderate\u2010to\u2010severe AD in adult patients with previous immunosuppressant exposure.<\/jats:p>","DOI":"10.1111\/1346-8138.17234","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T01:05:36Z","timestamp":1713834336000},"page":"759-771","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost\u2010effectiveness analysis of abrocitinib compared with standard of care in adult moderate\u2010to\u2010severe atopic dermatitis in Japan"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5354-7064","authenticated-orcid":false,"given":"Akio","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Dermatology, Graduate School of Biomedical and Health Sciences Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-7231","authenticated-orcid":false,"given":"Akira","family":"Yuasa","sequence":"additional","affiliation":[{"name":"Japan Access &amp; Value Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Kamei","sequence":"additional","affiliation":[{"name":"Japan Access &amp; Value Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Nagano","sequence":"additional","affiliation":[{"name":"Japan Access &amp; Value Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Murofushi","sequence":"additional","affiliation":[{"name":"HEOR, Value &amp; Access INTAGE Healthcare Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Bjerke","sequence":"additional","affiliation":[{"name":"Modeling and Analytics Lumanity  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Medical Affairs Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Public Health, School of Medicine International University of Health and Welfare  Narita Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00149-X"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020385"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00516-w"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.02.006"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.06.009"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15366"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14218"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16054"},{"key":"e_1_2_7_10_1","unstructured":"Regeneron Pharmaceuticals Inc.Regeneron announces approval of dupixent\u00ae (dupilumab) in japan for the treatment of atopic dermatitis.2018. Available from:https:\/\/newsroom.regeneron.com\/news\u2010releases\/news\u2010release\u2010details\/regeneron\u2010announces\u2010approval\u2010dupixentr\u2010dupilumab\u2010japan\u2010treatment\/"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100042"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16635"},{"key":"e_1_2_7_13_1","unstructured":"Pfizer Inc.Japan's MHLW approves Pfizer's CIBINQO\u00ae (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis.2021. Available from:https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/japans\u2010mhlw\u2010approves\u2010pfizers\u2010cibinqor\u2010abrocitinib\u2010adults"},{"key":"e_1_2_7_14_1","unstructured":"Pfizer Japan Inc.CIBINQO (abrocitinib) Package Inserts.2021[updated July 2023]. Available from:https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/672212_4490037F1026_1_04"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1191"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.11.008"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011"},{"key":"e_1_2_7_18_1","unstructured":"Ministry of Health Labour and Welfare.Guidelines for promoting the optimal use of baricitinib (Brand name: 2\u2010mg Olumiant tablets 4\u2010mg Olumiant tablets) Atopic dermatitis.2020[updated March 2024]. Available from:https:\/\/www.pmda.go.jp\/files\/000267565.pdf"},{"key":"e_1_2_7_19_1","unstructured":"Ministry of Health Labour and Welfare.Guidelines for promoting the optimal use of upadacitinib hydrate (brand name: 7.5\u2010mg Rinvoq tablets 15\u2010mg Rinvoq tablets 30\u2010mg Rinvoq tablets) Atopic dermatitis.2021. Available from:https:\/\/www.pmda.go.jp\/files\/000243653.pdf"},{"key":"e_1_2_7_20_1","unstructured":"Ministry of Health Labour and Welfare.Guidelines for promoting the optimal use of abrocitinib (Brand name: 200\u2010mg Cibinqo tablets 100\u2010mg Cibinqo tablets 50\u2010mg Cibinqo tablets) Atopic dermatitis.2022. Available from:https:\/\/www.pmda.go.jp\/files\/000249916.pdf"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00604-9"},{"key":"e_1_2_7_22_1","unstructured":"Canadian Agency for Drugs and Technologies in Health.Reimbursement review abrocitinib (Cibinqo).2023. Available from:https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2023\/SR0686\u2010Cibinqo.pdf"},{"key":"e_1_2_7_23_1","unstructured":"Institute for Clinical and Economic Review.JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value: Final evidence report.2023. Available from:https:\/\/icer.org\/wp\u2010content\/uploads\/2023\/02\/Atopic\u2010Dermatitis_Final\u2010Evidence\u2010Report_Unmasked_02272023.pdf"},{"key":"e_1_2_7_24_1","unstructured":"National Institute for Health and Care Excellence.[TA534] Dupilumab for treating moderate to severe atopic dermatitis.2018. Available from:https:\/\/www.nice.org.uk\/guidance\/TA534"},{"key":"e_1_2_7_25_1","unstructured":"National Institute for Health and Care Excellence.[TA681] Baricitinib for treating moderate to severe atopic dermatitis.2021. Available from:https:\/\/www.nice.org.uk\/guidance\/TA681"},{"key":"e_1_2_7_26_1","unstructured":"National Institute for Health and Care Excellence.[TA814] Abrocitinib tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis \u2013 Committee Papers.2022. Available from:https:\/\/www.nice.org.uk\/guidance\/ta814\/documents\/committee\u2010papers"},{"key":"e_1_2_7_27_1","unstructured":"Scottish Medicines Consortium.Dupilumab (Dupixent).2018. Available from:https:\/\/www.scottishmedicines.org.uk\/medicines\u2010advice\/dupilumab\u2010dupixent\u2010fullsubmission\u2010smc2011\/"},{"key":"e_1_2_7_28_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health National Institute of Public Health (C2H).Guideline for preparing cost\u2010effectiveness evaluation to the Central Social Insurance Medical Council.2022. Available from:https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462317000526"},{"key":"e_1_2_7_30_1","unstructured":"Canadian Agency for Drugs and Technologies in Health.Pharmacoeconomic report for Dupixient SR0636.2020. Available from:https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/sr0636\u2010dupixent\u2010pharmacoeconomic\u2010review\u2010report.pdf"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.23943"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.10.005"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17351"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_7_35_1","unstructured":"Pfizer Inc.Data on file.2022."},{"key":"e_1_2_7_36_1","unstructured":"National Institute of Population and Social Security Research.All Japan: Life Table Data Series.2022. Available from:https:\/\/www.ipss.go.jp\/p\u2010toukei\/JMD\/00\/index\u2010en.html"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0181-6"},{"key":"e_1_2_7_39_1","unstructured":"Ministry of Health Labour and Welfare.National Health Insurance Tarrif (revised in 2022).2022. Available from:https:\/\/www.mhlw.go.jp\/content\/12404000\/000907834.pdf"},{"key":"e_1_2_7_40_1","unstructured":"Organisation for Economic Co\u2010operation and Development.Exchange rates (yearly).2022. Available from:https:\/\/data.oecd.org\/conversion\/exchange\u2010rates.htm"},{"key":"e_1_2_7_41_1","unstructured":"Medical Data Vision.Website.2023. Available from:https:\/\/en.mdv.co.jp\/"},{"key":"e_1_2_7_42_1","unstructured":"Ministry of Health Labour and Welfare.National Health Insurance Drug Price List (revised in 2024).2024. Available from:https:\/\/www.mhlw.go.jp\/content\/12404000\/001218724.pdf"},{"key":"e_1_2_7_43_1","unstructured":"Statistics Bureau of Japan.Patient Survey 2020.2020. Available from:https:\/\/www.e\u2010stat.go.jp\/stat\u2010search\/files?page=1&layout=datalist&toukei=00450022&tstat=000001031167&cycle=7&tclass1=000001166809&tclass2=000001166811&tclass3=000001166812&tclass4=000001166813&tclass5val=0"},{"key":"e_1_2_7_44_1","unstructured":"Ministry of Health Labour and Welfare.Labour Force Survey 2021.2021. Available from:https:\/\/www.stat.go.jp\/data\/roudou\/2.html"},{"key":"e_1_2_7_45_1","unstructured":"National Tax Agency.Statistical Survey of Actual Status for Salary in the Private Sector 2021.2021. Available from:https:\/\/www.nta.go.jp\/publication\/statistics\/kokuzeicho\/minkan2021\/minkan.htm"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19378"},{"key":"e_1_2_7_47_1","unstructured":"Medicinr\u00e5det.The Danish Medicines Council methods guide for assessing new pharmaceuticals.2021. Available from:https:\/\/medicinraadet.dk\/media\/wq0dxny2\/the_danish_medicines_council_methods_guide_for_assessing_new_pharmaceuticals_version_1\u20102_adlegacy.pdf"},{"key":"e_1_2_7_48_1","unstructured":"Zorginstituut Nederland.Guideline for conducting economic evaluations in healthcare [in Dutch: Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg].2016. Available from:https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/publicatie\/2016\/02\/29\/richtlijn\u2010voor\u2010het\u2010uitvoeren\u2010van\u2010economische\u2010evaluaties\u2010in\u2010de\u2010gezondheidszorg\/richtlijn\u2010voor\u2010het\u2010uitvoeren\u2010van\u2010economische\u2010evaluaties\u2010in\u2010de\u2010gezondheidszorg.pdf"},{"key":"e_1_2_7_49_1","unstructured":"Dental and Pharmaceutical Benefits Agency.Allmanna rad: Om ekonomiska utvarderingar.2017. Available from:https:\/\/www.tlv.se\/download\/18.12550ff716050753615170a7\/1513253615658\/internationell_prisjamforelse_av_lakemedel_2017.pdf"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.007"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0132-3"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00774-2"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cia2.12163"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0618-5"},{"key":"e_1_2_7_55_1","unstructured":"Canadian Agency for Drugs and Technologies in Health.Guidelines for the economic evaluation of health technologies: Canada.2017. Available from:https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1265"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206714"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.019"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917006"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.059"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T11:15:04Z","timestamp":1763032504000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/1346-8138.17234"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17234","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"2024-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}